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Over the past 10 years, the Peruvian National Tuber-
culosis (TB) Program, the National Reference Laboratory 
(NRL), Socios en Salud, and US partners have worked to 
strengthen the national TB laboratory network to support 
treatment of multidrug-resistant TB. We review key lessons 
of this experience. The preparation phase involved estab-
lishing criteria for drug susceptibility testing (DST), selecting 
appropriate DST methods, projecting the quantity of DST 
and culture to ensure adequate supplies, creating biosafe 
laboratory facilities for DST, training laboratory personnel on 
methods, and validating DST methods at the NRL. Imple-
mentation involved training providers on DST indications, 
validating conventional and rapid ﬁ   rst-line DST methods 
at district laboratories, and eliminating additional delays in 
specimen transport and result reporting. Monitoring included 
ongoing quality control and quality assurance procedures. 
Hurdles included logistics, coordinating with policy, compet-
ing interests, changing personnel, communications, and 
evaluation. Operational research guided laboratory scale-
up and identiﬁ  ed barriers to effective capacity building. 
H
eightened awareness of the global threat of tuber-
culosis (TB) has been spurred, in part, by the wide-
spread prevalence of drug-resistant strains (1). Extensively 
drug-resistant TB (XDR TB) is associated with high death 
rates among patients co-infected with HIV and has led to 
renewed efforts to strengthen TB control (2,3) Program 
managers and policy makers face the urgent task of quickly 
scaling-up comprehensive TB programs, often in settings 
with minimal infrastructure. Although daunting, the task 
appears feasible in light of favorable early treatment out-
comes for multidrug-resistant TB (MDR TB) treatment 
programs, the growing cadre of technical experts, consen-
sus on TB and MDR TB management (4), and availability 
of global resources to fund programs (5,6).
From 1996 through 2005 in Peru, a consortium of 
institutions implemented one of the most comprehensive 
national MDR TB treatment programs in the world. One 
component of this effort was the Laboratory Improvement 
Project, which was charged with scaling-up laboratory ser-
vices to support MDR TB treatment. We encountered many 
lessons in expanding laboratory access to quality TB cul-
ture and drug susceptibility testing (DST). We summarize 
the key lessons that may be relevant for other settings where 
MDR TB treatment is being planned or implemented.
Background
TB incidence in Peru is among the highest in Latin 
America, at 108.2/100,000 persons in 2005 (Table 1) (7). 
In the densely populated periphery of Lima, where half of 
all national cases are detected, the risk for infection with 
Mycobacterium tuberculosis may be among the highest 
recently documented (8–10). Rates of MDR TB are also 
high, with a national prevalence of 3% among patients 
never treated for TB and 12.3% among previously treat-
ed patients (11). During 1990–2000, Peru implemented a 
model program based on the World Health Organization 
(WHO)–endorsed strategy of directly observed treatment, 
short course (DOTS) (12). Massive use of sputum smear 
microscopy and standardized ﬁ  rst-line treatment resulted in 
effective case detection and cure, with an overall decrease 
in TB incidence by the end of the decade (13). During that 
period, however, the rates of MDR TB increased (14). 
Because DOTS alone was insufﬁ  cient to control on-
going transmission of drug-resistant strains (15), Partners 
in Health (PIH), Harvard University, Massachusetts State 
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Laboratory Institute (MSLI), Socios en Salud, the Peru-
vian National Tuberculosis Control Program (NTP), and 
the Peruvian National Institute of Health (INS) initiated 
a collaborative MDR TB treatment effort in 1996 (16). 
Principles included individualized MDR TB treatment and 
monthly culture to monitor treatment response. Commu-
nity health promoters provided direct observation of all 
doses given outside health clinic hours. In 1997, the NTP 
implemented a standardized MDR TB treatment regimen, 
which achieved cure rates <50% (17). Although protocols 
changed over time, treatment failures, defaulters, and re-
lapses after ﬁ  rst-line treatment were generally referred for 
standardized MDR TB therapy. Those patients whose stan-
dardized treatments failed were, in turn, referred for indi-
vidualized treatment.
Expansion of Laboratory Capacity, 1996–2000
When we began this project, 1 level III laboratory, 
the National TB Reference Laboratory, performed DST 
on ﬁ  rst-line drugs; 57 level II laboratories performed my-
cobacterial culture, and ≈1,000 level I laboratories had 
smear microscopy capacity (Table 2). Because DST on 
second-line drugs was not available in Peru, isolates were 
initially sent to the MSLI until local capacity could be 
established.
As the MDR TB treatment program expanded in abso-
lute numbers and geographic coverage, so too did demand 
for laboratory services. From 1996 through 2000, the num-
ber of mycobacterial cultures and DSTs performed yearly 
more than doubled (Figures 1, 2). The process of program 
scale-up posed additional challenges in patient management, 
information systems, drug procurement, and regional imple-
mentation. Responding to these needs, the Bill & Melinda 
Gates Foundation awarded a grant for $45 million in 2000 
to establish a consortium called PARTNERS, whose princi-
pal task was to achieve national coverage of MDR TB treat-
ment in Peru and replicate this project elsewhere. Several 
key institutions were added to the initial group of collabora-
tors: WHO, the Centers for Diseases Control and Prevention 
(CDC), and the Task Force for Child Survival and Develop-
ment. Within the PARTNERS consortium, the Laboratory 
Improvement Project was established with specialists from 
MSLI, CDC, Harvard University, PIH, and INS.
Strategy to Scale-up Laboratory Services
NTP norms for DST indications have evolved over 
the past 10 years. This heterogeneous and dynamic process 
provided lessons on matching the choice of DST to pro-
grammatic strategies (Table 3). Salient aspects guiding lab-
oratory strategies include the choice of standardized versus 
individualized treatment, criteria for performing DST, rates 
of HIV and resistance to second-line drugs, and empiric 
management while awaiting results.
On the basis of projected numbers, DST needs would 
not be met unless DST on ﬁ  rst-line drugs was decentralized 
to regional laboratories in areas with high rates of TB and 
MDR TB. In choosing methods for decentralized DST, the 
INS matched method features with available resources in 
regional laboratories (Table 4). The need for a rapid DST 
method was clear. Given that it took an average of almost 
5 months to obtain results from a conventional DST per-
formed in Peru (18), physicians often had to make treat-
ment decisions empirically. Once results did arrive, they 
were no longer accurate because patients had been exposed 
to additional drugs in the interim, to which ampliﬁ  ed re-
sistance could have occurred. Rapid DST implemented at 
the decentralized level would be the most effective way 
of providing timely results and decompressing the central 
bottleneck of DST demand.
The INS decided that rapid DST should serve as an 
initial screening test. By quickly identifying resistance to 
702  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 14, No. 5, May 2008
Table 1. HIV and tuberculosis (TB), Peru, 2005* 
Characteristic Value
Total population  28,300,000
Population in Lima  7,300,000
Average life expectancy, y  69
Infant mortality rate  31/100,000 live births 
GDP per capita  $2,500
Population living in poverty  54%
National HIV prevalence  0.6%
Estimated no. HIV positive  60,000–80,000 
No. receiving HIV therapy  9,157
TB incidence  108/100,000
MDR TB in new patients   3%
MDR TB in previously treated patients  12.3%
TB in HIV patients  |30%
HIV in TB patients  |3%
MDR TB in co-infected patients  30%–47% 
Mortality rate among co-infected 
patients†
<38%
Mortality rate among MDR TB–HIV 
patients
<57%
*GDP, gross domestic product; MDR TB, multidrug-resistant TB. 
†Co-infected with HIV and TB but not necessarily MDR-TB. 
Table 2. Baseline laboratory capacity for diagnosis of tuberculosis, Peru, 1996–2000* 
Activity  Validation or quality control procedures No. establishments  No. performed/year 
Smear microscopy  Quality control of all AFB+ and 10% of AFB– results each 
trimester at regional level of laboratories 
987 1,164,198
Mycobacterial culture  Once a year, quality control of media culture  57 48,346
Drug susceptibility testing  External quality control in INPPAZ  1 1,045
*AFB, acid-fast bacilli; INPPAZ, Instituto Panamericano de Protección de Alimentos y Zoonosis. Scale-up of MDR TB Laboratory Services, Peru
isoniazid and rifampin, isolates with drug resistance could 
be sent to INS for full DST while standardized MDR TB 
treatment was started. With input from MSLI, the INS 
chose the Griess method. This method is a rapid colorimet-
ric method that uses Lowenstein-Jensen (LJ) medium pre-
pared with antimicrobial drugs (Figure 3) (19). Previously 
the method was validated as an indirect method; however, 
INS opted to implement it as a direct method, i.e., it is per-
formed directly with sputum. INS validation of this method 
yielded sensitivities and speciﬁ  cities of 99% and 100% to 
isoniazid and 94% and 100% to rifampin (20). Attributes 
of the Griess method are accuracy, fast turnaround time (21 
days), minimal additional equipment needs, inexpensive 
materials and reagents, and reproducibility in laboratories 
proﬁ  cient in mycobacterial culture.
On the basis of this rationale, the following plan was 
developed. Second-line DST (agar plate proportions meth-
od) would be implemented in the INS. Conventional ﬁ  rst-
line DST (proportions method, indirect variation by LJ me-
dium) would be performed at regional laboratories. Direct 
Griess method would be performed at regional laborato-
ries; and the indirect BACTEC-460 system (Becton Dick-
inson, Franklin Lakes, NJ, USA) for ﬁ  rst-line drugs would 
be implemented at INS for high-risk patients, including 
healthcare workers, HIV-positive patients, and pediatric 
patients.
Another priority was reducing the overall turnaround 
time of laboratory data, deﬁ  ned as the time when the patient 
is ﬁ  rst identiﬁ  ed at risk for MDR TB to the time that this 
determination has an effect on patient care. Before DST de-
centralization, we conducted an assessment of turnaround 
times in 2 health districts and conﬁ  rmed that laboratory 
efﬁ  ciency, including decentralization of DST and imple-
mentation of rapid methods, would have limited effect if 
pre- and post-DST processing delays were not addressed 
(18). These delays included specimen transport, specimen 
processing, dissemination of results to the health center, 
and scheduling of clinical evaluation once results were 
obtained. Of 924 samples processed over 16 months, the 
median turnaround time was 147 days; only 81 days were 
caused by DST processing. On the basis of these data, we 
worked with leaders at national and regional levels to de-
velop and implement strategies to reduce delays (Table 5).
The overall strategy for laboratory scale-up comprised 
the following activities. First, establish clear criteria for 
performing DST. Second, select DST methods for use 
within the TB program and indications for each method. 
Third, decentralize ﬁ  rst-line DST to 7 regional laboratories. 
Fourth, project the quantity of DST and cultures and ensure 
adequate supplies. Fifth, create biosafe laboratory facilities 
for DST. Sixth, train laboratory personnel on new meth-
ods. Seventh, train healthcare providers and level I labora-
tory personnel on DST indications. Eighth, validate DST 
methods, ﬁ  rst in the INS and then at each implementing 
site. Ninth, establish and enact quality control and quality 
assurance protocols. Tenth, eliminate additional delays in 
specimen transport and result reporting. These strategies 
were used and modiﬁ  ed in 3 phases of scale-up: prepara-
tion, implementation, and monitoring.
Preparation Phase
Key elements of the preparation phase were mobilizing 
political commitment (i.e., agreeing upon the strategic plan, 
obtaining adequate ﬁ  nancial and human resources, and for-
malizing collaborations and the respective roles of differ-
ent, competing and cooperating, institutions); establishing 
adequate laboratory infrastructure; and forming a skilled 
workforce. A needs assessment performed early in the 
project identiﬁ  ed the need for documented biologic safety 
cabinet (BSC) certiﬁ  cation and maintenance and repair of 
BSCs throughout the TB laboratory network. Because Peru 
had no trained personnel who could certify BSCs, a train-
ing program was developed and delivered with the help of 
MSLI and the Eagleson Institute in Sanford, Maine. The 
trained certiﬁ  ers then certiﬁ  ed and repaired BSCs for the 
TB laboratory network.
To proceed with decentralization efforts, INS contact-
ed directors of regional laboratories. Only 1 of the laborato-
ries met minimal space and biologic requirements to safely 
perform DST. The remaining 6 laboratories were asked to 
submit a proposal for laboratory renovations; only 3 were 
able to respond in a timely fashion. We explored why the 
other 3 laboratories did not respond and found that the ad-
ministrative time and technical expertise required to elabo-
rate a proposal was often not within the capacity of district 
and laboratory leaders.
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Figure 1. Mycobacterial cultures performed in Peru, by year.
Figure 2. Drug susceptibility testing (DST) performed in Peru, by 
method and year.PERSPECTIVE
We supported 2 laboratory renovations and discovered 
that substantial time and resources were required to com-
plete this process. Producing detailed and thorough tech-
nical proposals required substantial input from a range of 
experts, including architects; building, sanitary and elec-
trical engineers; and construction companies. We identi-
ﬁ  ed experts with interest and competence in designing TB 
health facilities and encouraged collaboration by team, 
with technical assistance from an engineer experienced in 
TB infection control at CDC. Cultivating such a team with 
specialized knowledge in TB infrastructure has proven to 
be an asset for Peru. This team has since worked on other 
projects to renovate TB clinics and laboratories.
Once elaborated, the proposals then required approval 
by the governmental institution responsible for approving 
renovations and construction of public health facilities. 
Construction for both projects was delayed by an average 
of 6 months because of these administrative requirements. 
District and laboratory leaders played an important role by 
making frequent inquiries into the status of the approval 
process. In the meantime, we purchased necessary equip-
ment, materials, and supplies.
Another step to expand DST capacity was the training 
and validation process for each DST method. MSLI trained 
INS in DST to second-line drugs by the agar plate propor-
tion method; validation was completed in 2005. Concomi-
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Table 3. Optimal DST characteristics depending on MDR TB management strategy, Peru* 
Programmatic and epidemiologic features Optimal DST characteristics 
Standardized versus individualized regimens 
  Standardized regimens for MDR  
  based on regional resistance patterns 
Centralized, complete DST (i.e., first- and second-line drugs) of representative samples to 
guide standardized treatment regimen; turnaround time less important 
  Individualized regimens  Rapid, point-of-care DST optimal to accommodate high demand and minimize turnaround 
time. Semi-individualized regimens may be constructed if only DST to first-line drugs 
performed. 
Who is tested for DST? 
  Narrow DST indications (e.g., treatment 
 failures  only) 
High pretest probability for MDR TB; therefore, optimal to perform DST to first- and 
second-line drugs to guide regimen design 
  Moderate DST indications (e.g.,  
  healthcare worker, smear-positive in  
  second month of DOTS) 
Rapid DST to first-line drugs to screen MDR TB versus non–MDR TB. If individualized 
treatment, drug-resistant samples may be referred for complete DST. Sensitivity may be 
more important than specificity because of greatest illness from failing to start appropriate 
treatment in patients with drug resistance. 
  Universal DST  Rapid DST to first-line drugs to screen MDR TB versus non–MDR TB. Rapid point-of-care 
testing (decentralized) optimal. If individualized treatment, drug-resistant samples may be 
referred for complete DST. Sensitivity may be more important than specificity. 
Epidemiologic features 
  Patients with smear-negative disease  
  (e.g., HIV, children) 
Direct DST by using liquid medium or indirect DST after culture by liquid medium. Rapid 
turnaround time important given high illness rates in these risk groups. 
  High rates of resistance to second-line  
 drugs  (XDR  TB) 
Complete DST if high rates of resistance to second-line drugs, including XDR. If limited 
resources, DST to first-line drugs plus key second-line drugs (e.g., quinolone, kanamycin) 
to enable identification of XDR TB cases. 
Management while awaiting DST results 
  Empiric first-line regimen  Greater risk for inadequate treatment of MDR TB cases; rapid testing more important 
  Empiric MDR TB regimen  Less risk for inadequate treatment of MDR TB cases, excess cost and toxicity for non–
MDR TB cases. Complete DST results permit adjustment of empiric MDR TB therapy. 
*DST, drug susceptibility testing; MDR TB, multidrug-resistant tuberculosis; XDR TB, extensively drug-resistant TB; DOTS, directly observed treatment, 
short course. 
Table 4. Considerations for decentralized drug susceptibility testing (DST) capacity for first-line drugs, Peru 
Criterion Ideal situation
Drugs to test  First-line DST; isoniazid and rifampin most important because empiric treatment regimen and 
further DST may follow 
Reproducibility  Because drug-resistant samples identified by regional DST, then referred to National 
Reference Laboratory for DST to second-line drugs, sensitivity most important 
Sample source  Direct method optimal for processing  
at local health clinic to minimize turnaround time 
Cost per sample  Low cost 
Time to obtain result  Rapid
Technical demand  Less technically demanding, less processing time 
Biologic safety risk  Low biosecurity risk 
Required equipment  Limited additional equipment
(refridgerated centrifuge) procured and maintained in local site 
Reagents and supplies  Commonly used reagents and supplies available through local vendors is preferable Scale-up of MDR TB Laboratory Services, Peru
tantly, INS trained regional laboratory personnel in DST of 
ﬁ  rst-line line drugs, by the LJ medium proportions method. 
To initiate rapid DST, the Griess method was validated ﬁ  rst 
at INS; then personnel from each implementing laboratory 
were trained in the method. Both conventional DST and 
rapid DST were validated at the regional laboratories. Sam-
ples were collected under program conditions. DST was 
performed by trained personnel in the regional laboratories. 
These same strains were then sent to INS for validation.
INS also validated BACTEC against LJ medium pro-
portions and sped the process by performing BACTEC 
culture followed by indirect BACTEC DST on ﬁ  rst-line 
line drugs. Validation was done for the AccuProbe meth-
od (Gen-Probe, Inc., San Diego, CA, USA) to identify M. 
tuberculosis and M. avium complex. Finally, INS leaders 
developed standard operating procedures, including proto-
cols for all laboratory methods, biosafety and equipment 
standards, and quality assurance and quality control pro-
cedures.
Other activities during the preparation stage were aimed 
at reducing turnaround time. We developed and piloted an 
electronic laboratory information system connecting INS, 
regional laboratories, and health centers to provide health 
personnel (physicians, nurses, and laboratory technicians) 
with real-time access to culture and DST results. To sup-
port the system, we worked with health district leaders to 
provide Internet access, computers, and Web access points 
at health centers (21). We also purchased 2 automobiles to 
aid in specimen transport. At the administrative level, NTP 
increased the frequency of MDR TB treatment–approval 
meetings to reduce the bottleneck of cases pending approv-
al for initiation of MDR TB treatment.
Implementation Phase
After successful completion of validation procedures 
in regional laboratories, DST was incorporated into pro-
grammatic services. Aggregate data on DST results were 
reviewed by each laboratory on a monthly basis to monitor 
rates of contamination, culture growth, and drug resistance. 
INS supervisors made frequent visits to these laboratories 
to monitor performance and troubleshoot any challenges. 
For instance, when low rates of culture growth were ob-
served among acid-fast bacilli smear-positive samples, 
smear microscopy slides from these samples were re-
viewed by a biologist and decontamination protocols were 
reviewed. During this period, we simultaneously trained 
healthcare personnel in workshops and one-on-one interac-
tions. Laboratory and TB program directors led workshops 
to review programmatic norms for soliciting each DST 
method and to explain the performance and characteristics 
of each method. Health workers were also trained to use 
the laboratory information system. Regional administrators 
trained providers in patient conﬁ  dentiality and established 
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Figure 3. Description and costs of the direct Griess method in Peru. 
A) Pan-susceptible Mycobacterium tuberculosis isolate. B) M. 
tuberculosis isolate resistant to isoniazid (INH) and rifampin (RIF). 
The left (control) tube in panel A and all tubes in panel B indicate 
mycobacterial growth. The costs of the test are US $5.30 per 
sample, including personnel, materials (items that can be reused), 
and supplies (reagents and consumable items), and US $4.80 per 
sample, including materials and supplies.PERSPECTIVE
a plan for sustained Internet access and computer mainte-
nance after the pilot phase of the information system. We 
secured the commitment of health center directors to guar-
antee that TB personnel would have access to the comput-
ers during designated hours because computers were rarely 
placed in the TB services areas to reduce the risk for theft 
and vandalism.
Monitoring Phase
Sustainable laboratory infrastructure depends on ad-
ministrative commitment and monitoring laboratory per-
formance quality. Throughout the entire planning and 
implementation stages, MSLI provided training to INS and 
regional laboratories in basic and method-speciﬁ  c quality 
control/quality assurance.
The appropriate use of DSTs and culture data by 
healthcare workers also required ongoing evaluation. Pre-
liminary data demonstrate that despite the reinforcement 
of NTP norms, health personnel often failed to adhere to 
NTP norms for DST (22). Approximately 50% of DSTs in 
2005 in Lima were requested for patients without an indica-
tion for testing by NTP norms. Of DSTs not meeting NTP 
norms, ≈28% of these were for patients who had MDR 
TB compared with 32.5% among those with NTP criteria. 
These ﬁ  ndings support the need for broadened indications 
for DST. Monitoring laboratory and programmatic perfor-
mance was not effective unless these data were fed back to 
healthcare personnel. An example is a series of reports gen-
erated by the information system and provided to labora-
tory and regional TB program directors (Table 6) (23,24).
TB management protocols, such as DST indications 
and optimal DST methods, are dynamic; they must respond 
to changes in regional epidemiology as well as the avail-
ability of resources. For example, decentralization of DST 
706  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 14, No. 5, May 2008
Table 5. Strategies to reduce turnaround time of culture and DST, Peru* 
Step
Median baseline 
turnaround time, d  Strategies used 
Goal turnaround 
time, d 
From time DST processed to 
DST result at INS 
81 Decentralize conventional and rapid DST methods  21
From receipt of DST result at 
intermediate laboratory to 
receipt of DST result at health 
establishment
6 Implement laboratory information system linking health 
centers, regional and national laboratories; improve transport 
of samples from health centers to regional laboratories 
1
From receipt of DST result at 
health establishment to patient 
reevaluation with DST result 
33 Train local providers to improve identification and referral of 
patients in need of MDR TB treatment; increase frequency of 
MDR TB treatment approval meetings; create new national 
culture/DST request form with DST indicators 
7
*DST, drug susceptibility testing; INS, Instituto Nacional de Salud; MDR TB, multidrug-resistant tuberculosis. 
Table 6. Automated reports generated by tuberculosis (TB) laboratory information system, Peru* 
Report Informed Purpose Type of access†
Frequency of information system access 
by healthcare center personnel 
Regional laboratory 
and TB director 
Maintain frequent use of 
information system to access 
real-time laboratory data 
Monthly report prepared 
by data administrator 
No. laboratory results entered at regional 
laboratory 
Regional laboratory  
and TB director 
Identify delays in data entry  Monthly report prepared 
by data administrator 
No. laboratory results verified and released 
to providers 
Regional laboratory  
and TB director 
Identify delays lags in result 
verification 
Monthly report prepared 
by data administrator 
DST results for any specified period 
grouped by every variable in request form 
Regional and INS 
laboratory director 
Report and identify trends in 
laboratory performance 
Constant
Culture results for any specified period 
grouped by every variable in request form 
Regional and INS 
laboratory director 
Report and identify trends in 
laboratory performance 
Constant
DST and cultures in process too long, DST 
missing reception date, DSTs needed to 
be entered into system, duplicate tests 
Regional and INS 
laboratory director 
Quality control  Constant
Rate of culture contamination; rate of 
negative culture growth from smear-
positive specimens 
Regional and INS 
laboratory director 
Identify trends in laboratory 
performance 
Constant
Persons with a positive culture for any 
specified date 
Regional and INS 
laboratory director 
Reporting to regional  
TB program 
Constant
Persons with new DST or culture results  Healthcare center 
personnel
Minimize turnaround time of 
laboratory results 
Constant and email 
notification
Tests that are in process and the number 
of days in process 
Healthcare center 
personnel
Inform personnel of when to 
expect results 
Constant
*DST, drug susceptibility testing; INS, Instituto Nacional de Salud.  
†Constant access indicates that laboratory users could view this information in the system at any time. Some reports let the user specify the start and end 
dates. Scale-up of MDR TB Laboratory Services, Peru
resulted in an increased demand for DST because of in-
creased awareness of MDR TB and availability of testing. 
Additionally, health professionals and patients perceived 
the beneﬁ  t of rapid, real-time laboratory data. This increase 
in demand is an example of how our ongoing monitoring 
and evaluation could be applied to reassess the use and ca-
pacity of laboratory services. Our preliminary data of ad-
herence to NTP indications for DST (22) and rates of MDR 
TB among risk groups (25) have helped inform modiﬁ  ca-
tions of NTP policy. The experience thus far in matching 
the appropriate DST methods to NTP norms should enable 
a rational application and operational assessment of prom-
ising new DST methods (26). Without adequately quantify-
ing and responding to an increase in DST demand, labora-
tory operations may become bottlenecked, and excessive 
demand on limited personnel could result in deviations 
from laboratory protocols and a decrease in laboratory 
performance. Figures 1 and 2 reﬂ  ect the level of labora-
tory expansion in Peru as of 2006, which demonstrates the 
trajectory of scale-up, not only in terms of DST, but for 
culture as well.
Lessons Learned
TB programs faced with incorporating MDR TB treat-
ment must often expand laboratory infrastructure far be-
yond existing capacity. Although laboratory improvement 
efforts in Peru have taken a decade to accomplish and are 
still evolving, several key lessons can be distilled from our 
experience.
Responding in Time and Stepwise, 
Overlapping Efforts to Prevent Delays
The introduction and decentralization of DST and cul-
ture capacity can involve a wide range of activities, rang-
ing from obtaining permits from national authorities to 
purchasing automobiles to streamline specimen transport. 
Attention to detail, the dedication of human resources to 
push these activities along, and parallel planning and coor-
dination of activities can receive inadequate priority among 
program planners. Although these logistics can be painful-
ly mundane, they are often the greatest obstacles, thus indi-
rectly causing the most serious illness due to excessive de-
lays. The recent outbreak of XDR TB among HIV-positive 
populations in KwaZulu-Natal, South Africa, demonstrates 
the need to scale-up laboratory services in a timely but cor-
rect manner (27).
Coordination of National Reference 
Laboratory and National TB Programs
Political commitment must include stable leadership; 
a strong central, coordinating unit; and a working relation-
ship between TB laboratories and a TB program (28). The 
importance of coordinating laboratory and programmatic 
efforts may seem obvious but cannot be overstated. Within 
the DOTS model, smear microscopy can be performed at 
health centers with local coordination with TB services. In 
contrast, MDR TB treatment requires more complex meth-
ods (culture, DST) and is usually performed and overseen 
at a central site. Strategies must be informed by NTP policy 
and vice versa. Coordination must persist because the needs 
of a TB program will likely change over time.
Importance of Operational Research
Our experience in Peru was informed by our operation-
al research. The proﬁ  le of a DST method and its character-
istics, when ﬁ  rst validated in a local laboratory, may be dif-
ferent from its performance, strengths, and weakness when 
it is operating under actual program conditions. Operation-
al assessment of a laboratory method or strategy is the sole 
means of understanding its effectiveness when considered 
within the larger context of how the method is used, associ-
ated complexities or challenges in its implementation, the 
mitigation of its effect caused by other system delays, and 
other factors. If tools to monitor laboratory performance 
are incorporated into information and reporting systems at 
the outset, effective operational research can be conducted 
with minimal additional resources, coupled with ongoing 
feedback, to create a sustainable laboratory system.
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